No connection

Search Results

ABUS vs INMD

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
INMD
InMode Ltd.
NEUTRAL
Price
$13.53
Market Cap
$857.2M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABUS
--
INMD
9.46
Forward P/E
ABUS
-27.41
INMD
8.84
P/B Ratio
ABUS
11.38
INMD
1.25
P/S Ratio
ABUS
61.92
INMD
2.31
EV/EBITDA
ABUS
-29.91
INMD
3.6

Profitability

Gross Margin
ABUS
-79.23%
INMD
78.53%
Operating Margin
ABUS
-727.31%
INMD
25.03%
Profit Margin
ABUS
-237.88%
INMD
25.33%
ROE
ABUS
-38.52%
INMD
13.53%
ROA
ABUS
-14.94%
INMD
6.88%

Growth

Revenue Growth
ABUS
-33.2%
INMD
6.1%
Earnings Growth
ABUS
--
INMD
-63.5%

Financial Health

Debt/Equity
ABUS
0.05
INMD
0.01
Current Ratio
ABUS
15.73
INMD
9.88
Quick Ratio
ABUS
15.52
INMD
8.55

Dividends

Dividend Yield
ABUS
--
INMD
--
Payout Ratio
ABUS
0.0%
INMD
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
INMD NEUTRAL

InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.

Strengths
Exceptional gross margins of 78.53%
Virtually debt-free balance sheet (Debt/Equity 0.01)
Extreme short-term liquidity with a Current Ratio of 9.88
Risks
Severe earnings contraction (-63.50% YoY)
Strongly bearish technical momentum (0/100 trend score)
Deteriorating fundamental health as indicated by Piotroski F-Score (3/9)

Compare Another Pair

ABUS vs INMD: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and InMode Ltd. (INMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile